<DOC>
	<DOCNO>NCT02844114</DOCNO>
	<brief_summary>This study evaluate effect serum level Superoxide Dismutase ( SOD ) , Malondialdehyde ( MDA ) , pro-inflammatory factor , stress hormone Glutathione peroxidase ( GSH-PX ) tumor patient treatment Ganoderma lucidum spore base combination chemotherapy . Half participant receive Ganoderma lucidum spore chemotherapy combination , half receive placebo chemotherapy . Study design : Phase 2 . Experimental : Ganoderma lucidum spore &amp; Chemotherapy ; Placebo Comparator : Placebo &amp; Chemotherapy . Outcome Measure : 1 . The life quality participant assess use Functional Assessment Cancer Therapy-General ( FACT-G ) questionnaire initial diagnosis ( baseline ) 42 day treatment ; 2 . Investigators assess Procedural mortality factor ligand 1 ( PD-L1 ) expression prospectively tumour cell tumour-infiltrating immune cell VENTANA PD-L1 immunohistochemistry assay ; 3 . National Cancer Institute Common Toxicity Criteria . Statistical analysis : All experiment result analyze Statistical Product Service Solutions ( SPSS ) software ( version 16.0 ) . Data present mean±standard deviation analyse one-way ANOVA . Semi-quantitative data compare use Kruskal- Wallis nonparametric analysis . The result consider statistically significant P &lt; 0.05 .</brief_summary>
	<brief_title>Clinical Study Ganoderma Lucidum Spore Combined With Chemotherapy</brief_title>
	<detailed_description>Ganoderma lucidum spore , natural substance widely recognize used tumor patient nutritive value . The effect prove Ganoderma lucidum spore polysaccharide , triterpene compound trace element , combine chemotherapy reduce toxicity enhance efficacy patient . Ganoderma lucidum spore reduce bone narrow depression , gastrointestinal mucosal damage enhance immunity . Previous study report Ganoderma lucidum spore antivirus , antineoplastic , decrease blood lipid , hypoglycemic anti-hypoxic activity . The objective study observe effect Ganoderma lucidum spore base combination chemotherapy treatment patient . And detect serum level SOD , MDA , pro-inflammatory factor , stress hormone GSH-PX .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Have diagnose definitely cytopathology examination image method . Eastern Cooperative Oncology Group ( ECOG ) score standard : 02 . Survival time may last 3 month . Normal electrocardiogram change . WBC≧4.0×10*9/L , PLT≧1.5×10*9/L , HB≧100.0g/L Have cardiac disease , myocardial infarction past 6 month . Receiving effective treatment currently . Have diabetes another chronic metabolic disorder ( BIM &lt; 18 &gt; 25 ) . Serious pyogenic chronic infection . Have hematologic disease coagulation dysfunction . Unhealed serious cerebral disease tumor , depression disorder , senile dementia mental disease . Pregnant lactation woman , allergic constitution . Combined liver , kidney , blood system Primary serious disease , mental patient . Within past 4 week participate clinical trial patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ganoderma Lucidum Spore</keyword>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
</DOC>